Prostate cancer, Prostate, Prostatectomy, Internal medicine and Prostate-specific antigen are his primary areas of study. His Prostate cancer study combines topics from a wide range of disciplines, such as Cancer research, Gynecology, Surgery and Urology. The study incorporates disciplines such as Immunohistochemistry, Pathology, Gene expression, Stage and Adenocarcinoma in addition to Prostate.
His Prostatectomy research integrates issues from Prostate neoplasm, Biopsy, Salvage therapy, Erectile dysfunction and Prospective cohort study. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology and Oncology. His Prostate-specific antigen research includes elements of Biochemical recurrence, Radiation therapy, Proportional hazards model and Retrospective cohort study.
Judd W. Moul spends much of his time researching Prostate cancer, Internal medicine, Prostatectomy, Prostate and Oncology. Prostate-specific antigen is the focus of his Prostate cancer research. His Prostate-specific antigen research is multidisciplinary, incorporating elements of Salvage therapy, Proportional hazards model and Retrospective cohort study.
His work on Internal medicine is being expanded to include thematically relevant topics such as Endocrinology. In his study, Hazard ratio is inextricably linked to Urology, which falls within the broad field of Prostatectomy. His Prostate study incorporates themes from Cancer research, Carcinoma, Cohort, Pathology and Adenocarcinoma.
His primary areas of investigation include Prostate cancer, Internal medicine, Oncology, Prostatectomy and Urology. Judd W. Moul has researched Prostate cancer in several fields, including Biopsy, Prostate and Gynecology. Judd W. Moul interconnects Endocrinology and MEDLINE in the investigation of issues within Internal medicine.
His research integrates issues of Stage, Orchiectomy, Disease and Genitourinary Cancers in his study of Oncology. He combines subjects such as Proportional hazards model, Radiation therapy, Surgery and Cohort with his study of Prostatectomy. Judd W. Moul has included themes like Clinical endpoint and Hazard ratio in his Urology study.
Judd W. Moul focuses on Prostate cancer, Internal medicine, Oncology, Prostate and Urology. The various areas that he examines in his Prostate cancer study include Gynecology and Surgery. As part of his studies on Internal medicine, he often connects relevant subjects like Endocrinology.
His study in Oncology is interdisciplinary in nature, drawing from both Androgen deprivation therapy, Androgen, Disease, Biochemical recurrence and Orchiectomy. His research in Prostate intersects with topics in Stage, Newly diagnosed, Biopsy and Radiation therapy. His work in Urology addresses subjects such as Prostatectomy, which are connected to disciplines such as Erectile dysfunction, Sexual function and Retrospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Ian Thompson;James Brantley Thrasher;Gunnar Aus;Arthur L. Burnett.
The Journal of Urology (2007)
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
Michael S. Cookson;Gunnar Aus;Arthur L. Burnett;Edith D. Canby-Hagino.
The Journal of Urology (2007)
Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men
Ted O. Morgan;Steven J. Jacobsen;William F. McCarthy;Debra J. Jacobson.
The New England Journal of Medicine (1996)
Surrogate End Point for Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy
Anthony V. D’Amico;Judd W. Moul;Peter R. Carroll;Leon Sun.
Journal of the National Cancer Institute (2003)
Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers
Jaya P. Gaddipati;David G. McLeod;Howard B. Heidenberg;Isabell A. Sesterhenn.
Cancer Research (1994)
Cancer-Specific Mortality After Surgery or Radiation for Patients With Clinically Localized Prostate Cancer Managed During the Prostate-Specific Antigen Era
Anthony V. D’Amico;Judd Moul;Peter R. Carroll;Leon Sun.
Journal of Clinical Oncology (2003)
Pathologic Variables and Recurrence Rates As Related to Obesity and Race in Men With Prostate Cancer Undergoing Radical Prostatectomy
Christopher L. Amling;Robert H. Riffenburgh;Leon Sun;Judd W. Moul.
Journal of Clinical Oncology (2004)
Prostate specific antigen only progression of prostate cancer
Judd W. Moul.
The Journal of Urology (2000)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome
Gyorgy Petrovics;Aijun Liu;Syed Shaheduzzaman;Bungo Furasato.
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Susan Halabi;Chen-Yen Lin;W. Kevin Kelly;Karim S. Fizazi.
Journal of Clinical Oncology (2014)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: